Graham Bothamley
YOU?
Author Swipe
View article: Correction to Diagnostic accuracy and predictive value of the QuantiFERON-TB gold plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet study Lancet Reg Health Eur 57 (2025) 101416 LLRHEUROPE-D-25-00310
Correction to Diagnostic accuracy and predictive value of the QuantiFERON-TB gold plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet study Lancet Reg Health Eur 57 (2025) 101416 LLRHEUROPE-D-25-00310 Open
View article: Diagnostic accuracy and predictive value of the QuantiFERON-TB gold plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet study
Diagnostic accuracy and predictive value of the QuantiFERON-TB gold plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet study Open
View article: A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists
A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists Open
Background: In the field of tuberculosis and non-tuberculous mycobacterial (NTM) disease we are looking back on an exciting year 2024 with more than 10,000 publications listed in PubMed. Methods: Our aim, to review the scientific literatur…
View article: Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy
Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy Open
Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approved label for pretomanid restricts its use to the regimen comprising bedaquiline, pretomanid and linezolid (BPaL) and only for extensi…
View article: Tuberculosis in adult migrants in Europe: a TBnet consensus statement
Tuberculosis in adult migrants in Europe: a TBnet consensus statement Open
Introduction Global migration has increased in recent decades owing to war, conflict, persecution and natural disasters, but also secondary to increased opportunities related to work or study. Migrants’ risk of tuberculosis (TB) differs de…
View article: Effect of Migrant-Sensitive Health Care in Europe: A Multicentric Retrospective TBnet Cohort Study
Effect of Migrant-Sensitive Health Care in Europe: A Multicentric Retrospective TBnet Cohort Study Open
View article: Recent Travel and Tuberculosis in Migrants: Data From a Low-Incidence Country
Recent Travel and Tuberculosis in Migrants: Data From a Low-Incidence Country Open
Tuberculosis (TB) incidence rates among migrants are higher than those in low-incidence countries. We evaluated smear-positive, pulmonary TB notifications of foreign-born individuals, comparing time since arrival and time since last return…
View article: Multidrug-resistant tuberculosis: diagnosis, checklists, adverse events, advice and outcomes
Multidrug-resistant tuberculosis: diagnosis, checklists, adverse events, advice and outcomes Open
The account of MDR-TB in Finland describes current practice. Genetic testing of primary specimens, whole-genome sequencing, supportive directly observed therapy, checklists and national consilia will contribute to further improvements i…
View article: Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study
Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study Open
View article: Co-administration of treatment for rifampicin-resistant tuberculosis and chronic hepatitis C virus infection: a TBnet and ESGMYC study
Co-administration of treatment for rifampicin-resistant tuberculosis and chronic hepatitis C virus infection: a TBnet and ESGMYC study Open
Concomitant treatment for chronic hepatitis C virus infection and multidrug-resistant tuberculosis is safe and effective.
View article: The monocyte-to-lymphocyte ratio: Sex-specific differences in the tuberculosis disease spectrum, diagnostic indices and defining normal ranges
The monocyte-to-lymphocyte ratio: Sex-specific differences in the tuberculosis disease spectrum, diagnostic indices and defining normal ranges Open
Background The monocyte-to-lymphocyte ratio (MLR) has been advocated as a biomarker in tuberculosis. Our objective was to evaluate its clinical value and associations. Methods Blood counts, inflammatory markers and clinical parameters were…
View article: Male Sex Bias in Immune Biomarkers for Tuberculosis
Male Sex Bias in Immune Biomarkers for Tuberculosis Open
Males have a bias toward developing sputum smear-positive pulmonary tuberculosis, whereas other forms of the disease have an equal sex ratio. Immune responses are known to be affected by estrogen and testosterone. Biomarkers may therefore …
View article: The monocyte-to-lymphocyte ratio: defining a normal range, sex-specific differences in the tuberculosis disease spectrum and diagnostic indices
The monocyte-to-lymphocyte ratio: defining a normal range, sex-specific differences in the tuberculosis disease spectrum and diagnostic indices Open
Background The monocyte-to-lymphocyte ratio has been advocated as a biomarker in tuberculosis. Our objective was to evaluate its clinical role in diagnosis, prognosis and treatment outcome. Methods Complete blood counts from an unselected …
View article: Use and impact of molecular methods for detecting drug‐resistant TB
Use and impact of molecular methods for detecting drug‐resistant TB Open
International audience
View article: Face-mask sampling or sputum to diagnose lung tuberculosis?
Face-mask sampling or sputum to diagnose lung tuberculosis? Open
More than a third of people estimated to have tuberculosis in 2018 were undiagnosed or detected but not notified.1WHOGlobal tuberculosis report.https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdfDate: 2019Date acc…
View article: Referee report. For: Intervening along the spectrum of tuberculosis: meeting report from the World TB Day nanosymposium in the Institute of Infectious Disease and Molecular Medicine at the University of Cape Town [version 3; peer review: 2 approved]
Referee report. For: Intervening along the spectrum of tuberculosis: meeting report from the World TB Day nanosymposium in the Institute of Infectious Disease and Molecular Medicine at the University of Cape Town [version 3; peer review: 2 approved] Open
View article: Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Open
Background: The American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America jointly sponsored this new practice guideline on the treatment of d…
View article: Developing a pathway for the diagnosis and management of ocular tuberculosis. The pan-LOndon Ocular tuberculosis Pathway—LOOP
Developing a pathway for the diagnosis and management of ocular tuberculosis. The pan-LOndon Ocular tuberculosis Pathway—LOOP Open
View article: Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance
Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance Open
Introduction 2018 World Health Organization (WHO) guidelines for the treatment of isoniazid (H)-resistant (Hr) tuberculosis recommend a four-drug regimen: rifampicin (R), ethambutol (E), pyrazinamide (Z) and levofloxacin (Lfx), with or wit…
View article: Management of patients with multidrug-resistant tuberculosis
Management of patients with multidrug-resistant tuberculosis Open
The emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at least rifampicin and isoniazid) represents a growing threat to public health and economic growth. Never before in the history of mankind have more patie…
View article: The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation
The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation Open
International audience
View article: Introduction
Introduction Open
View article: Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study
Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study Open
Background Despite a recent decline in the annual incidence of tuberculosis (TB) in the UK, rates remain higher than in most Western European countries. The detection and treatment of latent TB infection (LTBI) is an essential component of…
View article: Prognostic value of interferon-γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study
Prognostic value of interferon-γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study Open
View article: QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study
QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study Open
QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study.
View article: Diabetes mellitus and latent tuberculosis infection: baseline analysis of a large UK cohort
Diabetes mellitus and latent tuberculosis infection: baseline analysis of a large UK cohort Open
We conducted a cross-sectional analysis of baseline data from a UK cohort study which enrolled participants at risk of latent tuberculosis infection (LTBI, defined as a positive result for either of the two interferon gamma release assays)…
View article: ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update
ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update Open
The International Standards for Tuberculosis Care define the essential level of care for managing patients who have or are presumed to have tuberculosis, or are at increased risk of developing the disease. The resources and capacity in the…
View article: Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries
Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries Open
Conventional standard MDR-TB treatment regimens resulted in a higher frequency of failure compared with individualized treatments. Overall, cure from MDR-TB is substantially more frequent than previously anticipated, and poorly reflected b…
View article: Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond
Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond Open
As recommended by the World Health Organization (WHO), optimal management of MDR-TB cases can be ensured by a multi-speciality consultation body known as 'TB Consilium'. This body usually includes different medical specialities, competence…
View article: P164 Qft-plus: do the peptides in the tb2 tube induce a t suppressor response in some subjects?
P164 Qft-plus: do the peptides in the tb2 tube induce a t suppressor response in some subjects? Open
Introduction The revised QuantiFERON-TB Gold assay (QFT-Plus) has an extra tube (TB2), containing peptides thought to stimulate CD8 +T cells; TB7 antigen is no longer included. The test is designed to detect latent tuberculosis infection. …